How First-Line Therapy is Changing in non-Transplant Eligible Multiple Myeloma Patients

Area of Science:

• Hematology
• Oncology
• Geriatrics

Background:

• Multiple myeloma treatment has advanced, but many patients are ineligible for transplantation.
• Treatment for non-transplant eligible patients is challenging due to disease heterogeneity and limited options.
• The concept of frailty is increasingly recognized as crucial for tailoring therapy in older adults.

Purpose of the Study:

• To review recent advances in multiple myeloma treatment for patients ineligible for transplantation.
• To highlight the role of frailty assessment in personalizing treatment strategies.
• To discuss novel therapeutic approaches and their impact on patient outcomes.

Main Methods:

• Review of current literature on multiple myeloma treatment strategies.
• Analysis of the impact of frailty assessment on treatment adaptation.
• Evaluation of novel therapies including monoclonal antibodies, quadruplet regimens, and cell-directed therapies.

Main Results:

• CD38 monoclonal antibody combinations, such as daratumumab-lenalidomide-dexamethasone, show significant progression-free and overall survival benefits.
• Frailty assessment allows for optimized treatment schedules and dosages, reducing side effects and toxicity.
• Emerging therapies like bispecific antibodies and CAR-T treatment demonstrate high efficacy and minimal residual disease negativity.

Conclusions:

• Personalized treatment approaches, incorporating frailty assessment, are vital for non-transplant eligible multiple myeloma patients.
• Novel combinations and cell-directed therapies are transforming outcomes and may expand eligibility for intensive treatments.
• These advancements offer profound and durable results, improving survival and quality of life.